ImmuPharma PLC (LON:IMM)

ImmuPharma PLC (LON:IMM)

Share Price
11.79 p
-1.81 (-13.31 %)
Market Cap
£16.44 m
Proactive Investors - Run By Investors For Investors

ImmuPharma PLC RNS Release

Technology review published-Nature Communications

RNS Number : 0641R
Immupharma PLC
26 February 2019


RNS REACH                                                                                                                                             26 February 2019



ImmuPharma PLC

("ImmuPharma" or the "Company")


Technology review published in Nature Communications


ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce that on 25 February 2019, the peer reviewed research journal 'Nature Communications' published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl ("Ureka"), ImmuPharma's subsidiary.


Ureka, based at the IECB in Bordeaux, France, is carrying out research into novel peptide molecules to generate drug candidates for many diseases.  The publication describes for the first time the unique properties of oligourea foldamers as a tool to improve the pharmaceutical properties of peptides. Further improvements not yet described here are related to more focused medical indications. One of the first focus areas has been GLP-1 analogues for the treatment of Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) as  proof of concept for Ureka's technology.

Further applications of the Urelix™ technology include protein/protein interactions, notably in cancer, and improvement of marketed efficacious peptides allowing additional long lasting patent protection, paving the way for a life cycle management franchise.  Novel patented technologies are also currently implemented to cover other aspects of the improvement of peptides including potential oral delivery.


The publication was entitled: "Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo" and was authored by a number of researchers working within Ureka including Dr Robert Zimmer, ImmuPharma's Chief Scientific Officer and Dr Sébastien R. Goudreau, Head of Research at Ureka. 

Introduction to the Publication

Peptides have gained so much attention in the last decade that they are now part of the main strategies, with small molecules and biologics, for developing new medicines. Despite substantial progress, the successful development of peptides as drugs still requires a number of limitations to be addressed, including short in vivo half-lives and poor membrane permeability.


Commenting, Dr Robert Zimmer, ImmuPharma's Chief Scientific Officer, said: "I am very proud of the achievement of the research team in Ureka since it started in 2014, having built a team of skilled people and expanded our collaboration with the CNRS, developing an exciting technology backed by a strong patent portfolio. As such, a pleasing validation of years of research by our scientific team and collaborators, giving us further confidence in the long term potential of our Ureka platform."


Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said: "Natural peptides play key roles in human biological processes and are effective and selective signaling molecules that bind to specific receptors on cells.  Using natural peptides as drugs is not so effective because they are  quickly broken down.  To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs. The global peptide therapeutics market achieved sales of $30 billion in 2018."


The full paper can now be downloaded from: or accessed via Nature Communications website:



For further information please contact:


ImmuPharma plc (

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer


Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496



SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev


Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes


SI Capital (Joint Broker)

Nick Emerson


+44 (0) 203 368 8974




+44 (0) 203 815 8880



+44 (0) 1483 413500













About Nature Communications

Nature Communications is an open access journal that publishes high-quality research from all areas of the natural sciences.  Papers published by the journal represent important advances of significance to specialists within each field.  For more information go to:

About the IECB

The Institut Européen de Chimie et Biologie (European Institute of Chemistry and Biology) is an international and interdisciplinary research team incubator, placed under the joint authority of the CNRS, Inserm and the University of Bordeaux.  The CNRS is a public organization under the responsibility of the French Ministry of Education and Research.  The CNRS is top of the Nature Index (The Nature Index ranks publication productivity and is one indicator of global high-quality research output ) and has over 31,000 staff and €3.2 bn annual budget. 



















This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

ImmuPharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use